{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:06:41Z","timestamp":1788883601127,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007259","name":"Stony Brook University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX005260-01"],"award-info":[{"award-number":["BX005260-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.102997","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:59:59Z","timestamp":1782889199000},"page":"102997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"Erick M.","family":"Intriago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amartya","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan Y.","family":"Pesselev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Coant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-7458","authenticated-orcid":false,"given":"Jingfang","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102997_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omtn.2026.102997_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd1612","article-title":"Erlotinib hydrochloride","volume":"4","author":"Dowell","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.102997_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102997_bib4","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","article-title":"Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer","volume":"29","author":"Blaquier","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.102997_bib5","article-title":"Challenges and opportunities in microRNA-based cancer therapeutics","volume":"6","author":"Ju","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtn.2026.102997_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.102997_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.102997_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.omto.2023.02.007","article-title":"Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer","volume":"28","author":"Hwang","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtn.2026.102997_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbrc.2017.06.041","article-title":"MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1","volume":"490","author":"Ma","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2026.102997_bib10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2174\/1568009621666210415094350","article-title":"MiR-129-5p Promotes Radio-sensitivity of NSCLC Cells by Targeting SOX4 and RUNX1","volume":"21","author":"Xue","year":"2021","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.omtn.2026.102997_bib11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/1759-7714.14336","article-title":"miR-129-2 upregulation induces apoptosis and promotes NSCLC chemosensitivity by targeting SOX4","volume":"13","author":"Zhou","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.omtn.2026.102997_bib12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ijc.30739","article-title":"PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia","volume":"141","author":"Guo","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtn.2026.102997_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/abbs\/gmz096","article-title":"miR-129-5p suppresses proliferation, migration, and induces apoptosis in pancreatic cancer cells by targeting PBX3","volume":"51","author":"Qiu","year":"2019","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.omtn.2026.102997_bib14","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.18632\/oncotarget.3254","article-title":"A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ","volume":"6","author":"Tan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2026.102997_bib15","doi-asserted-by":"crossref","first-page":"51922","DOI":"10.18632\/oncotarget.10458","article-title":"YAP promotes erlotinib resistance in human non-small cell lung cancer cells","volume":"7","author":"Hsu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2026.102997_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4589","article-title":"A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components","volume":"12","author":"Nilsson","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102997_bib17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2026.102997_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.193","article-title":"miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer","volume":"4","author":"Karaayvaz","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2026.102997_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311277","article-title":"Docetaxel and Gemcitabine Modulate Cellular Effects and Long Non-Coding RNA Profiles in Non-Small Cell Lung Cancer","volume":"26","author":"Tirpe","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.102997_bib20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines","volume":"9","author":"Holbeck","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omtn.2026.102997_bib21","first-page":"209","article-title":"Gemcitabine for the treatment of advanced nonsmall cell lung cancer","volume":"2","author":"Toschi","year":"2009","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omtn.2026.102997_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3724\/abbs.2022023","article-title":"HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer","volume":"54","author":"Lei","year":"2022","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.omtn.2026.102997_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1476-4598-13-165","article-title":"HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma","volume":"13","author":"Pan","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2026.102997_bib24","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.neo.2017.10.003","article-title":"YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC","volume":"19","author":"Ghiso","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.omtn.2026.102997_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2016.04.089","article-title":"Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance","volume":"474","author":"Lee","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2026.102997_bib26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/0008-5472.CAN-17-3139","article-title":"The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1","volume":"78","author":"Janse van Rensburg","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.102997_bib27","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-17-2572","article-title":"PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer","volume":"24","author":"Lamprecht","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.102997_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.27990","article-title":"Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer","volume":"133","author":"Shevchenko","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtn.2026.102997_bib29","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ccell.2023.04.003","article-title":"Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators","volume":"41","author":"Obradovic","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2026.102997_bib30","article-title":"A phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia","author":"Ktoridou-Valen","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.omtn.2026.102997_bib31","article-title":"A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.102997_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-4598-10-98","article-title":"The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-kappaB activity and down-regulating Bfl-1","volume":"10","author":"Kim","year":"2011","journal-title":"Mol. Cancer"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312600168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312600168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:07:02Z","timestamp":1788880022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225312600168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S216225312600168X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102997","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102997"}}